Corus Dental sponsors mandate Houlihan Lokey to review options

The company is expected to be marketed off an EBITDA in the region of EUR 40m to EUR 50m, said two of the sources, although one of them noted that a portion of that is from a deep M&A pipeline. Corus Dental's current EBITDA stands at around EUR 30m-EUR 35m, this second source added.

The process is tipped to launch post the European summer break, said one of the sources.

Corus Dental explored a refinancing last year, to secure an acquisition line to fund further bolt-ons, as reported by Unquote's sister publication Debtwire. One of the sources said BlackRock refinanced the business on the back of that process, which was led by Lincoln International.

In the second quarter of this year, Corus Dental's two sponsors had been close to appointing either Houlihan Lokey or Jefferies in a bid to find a new strategic partner, as per a media report.

Healthcare-focused PE firm Careventures formed Corus in 2015. The group now owns more than 84 laboratories in nine European countries and has reported revenue of more than EUR 180m, according to the sponsor's website. Quadrum Capital joined the shareholder structure in March 2022 when Corus Dental merged with the former's portfolio company Signadens.

The two sponsors were to own 70% of the enlarged Corus Dental, with Careventures remaining the primary shareholder, according to a Spanish-language media report at the time of the merger. The remaining 30% were to be held by directors of the different laboratories acquired, as well as the Corus management team.

Houlihan Lokey, Careventures, Quadrum Capital and BlackRock did not respond to requests for comment.

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Exits
• Southern Europe
• Benelux
• Healthcare
• Spain
• Netherlands
• Houlihan Lokey
• Mergermarket